Impact Biomedicines' exit this week for a whopping $7B is the largest since AbbVie's $10B+ acquisition of Stemcentrx in 2016. In all, 14 cancer therapy companies have exited for over $1B since 2014.
Newly-public rival HelloFresh faces many of the same obstacles as Blue Apron, but has recently seen positive sales growth in the US.
The venture capital funnel shows just how brutal the VC game is.
New Enterprise Associates leads US VC firms in 2017 IPO exits.
Overall exit activity in digital health has dipped.